Drugs / ION547
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04934891 | Mar 2021 → Sep 2022 | — | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ION547 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04934891 ↗ |
| Action | Inhibit | “antisense inhibitor ION547” NCT04934891 ↗ |
| Modality | Antisense oligonucleotide | “antisense inhibitor ION547” NCT04934891 ↗ |